Synopsis: HSBC has maintained a ‘Buy’ rating on this leading private hospital chain with a target price of ₹1,175, implying an upside of nearly 25%, backed by capacity expansion, improving margins, and continued support from parent IHH Healthcare. The brokerage expects PAT to double between FY26 and FY29.
India’s private healthcare sector continues to attract institutional conviction, and one of its leading names is back in focus after a global brokerage reinforced its long-term bullish stance. With hospital networks expanding, occupancy trends improving, and profitability on a steady upward curve, the company is drawing renewed attention as a compounding healthcare play.
With a market capitalization of approximately Rs.71,276 crore, the shares of Fortis Healthcare were trading at around Rs.942 per share, with a 52-week range of Rs.1,104.30 to Rs.702. It is trading at a P/E of approximately 66x.
HSBC’s Buy Call
HSBC maintained its ‘Buy’ rating on Fortis Healthcare with a target price of Rs.1,175 per share, implying an upside of nearly 25% from the current market price of Rs.942. The brokerage’s conviction rests on three pillars: steady financial backing from promoter IHH Healthcare, strong earnings growth visibility through FY29, and the possibility of a direct capital infusion from IHH that could serve as a meaningful re-rating catalyst.
HSBC expects PAT to double between FY26 and FY29, driven by ongoing capacity additions, rising occupancy levels across key facilities, and sustained operating margin improvement. The brokerage views Fortis as one of the stronger structural growth stories within Indian private healthcare.
Business and Financial Overview
FY26 in Numbers
For FY26, Fortis Healthcare reported consolidated revenue of Rs.9,128 crore, up 17.3 percent year-on-year. Operating EBITDA grew 31.3 percent to Rs.2,085 crore, with margins expanding to 22.8 percent from 20.4 percent in FY25. Profit After Tax came in at Rs.1,064 crore, rising 31.5 percent over the prior year. The board has recommended a dividend of Rs.1 per share for FY26.
Q4 FY26 Performance
For Q4 FY26, consolidated revenue stood at Rs.2,365 crore, up 17.8 percent year-on-year. Operating EBITDA grew 22.2 percent to Rs.531 crore, with margins at 22.5 percent versus 21.7 percent in Q4 FY25. PAT for the quarter came in at Rs.271 crore, up 44.2 percent. The hospital business contributed revenue of Rs.2,023 crore, growing 19 percent, while the diagnostics arm (Agilus) posted gross revenues of Rs.387 crore, up 11.1 percent.
Capacity and Expansion
Fortis added approximately 500 beds to its network during FY26 through the acquisitions of People Tree Hospital in Bengaluru and Shrimann Hospital in Jalandhar, alongside a long-term lease for a facility in Greater Noida. The company has planned capacity additions of approximately 1,800 beds between FY27 and FY30, with a beds CAGR of 6.5 percent through FY31. Its top six specialties, Cardiac, Oncology, Orthopedics, Neurology, Gastroenterology, and Renal Sciences, grew 18.9 percent in FY26 and contributed around 62 percent of hospital revenues.
For Investors
HSBC’s sustained Buy call, combined with a doubling PAT target by FY29, positions Fortis Healthcare as one of the more compelling long-term compounders in Indian healthcare. Expanding bed capacity, improving facility-level margins, and the prospect of IHH-backed capital support strengthen the investment case. Investors may, however, wish to track acquisition integration, occupancy ramp-up at newer facilities, and execution consistency over the coming quarters.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
